These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15020221)

  • 1. Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU.
    Tamura M; Ajayi T; Allmond LR; Moriyama K; Wiener-Kronish JP; Sawa T
    Biochem Biophys Res Commun; 2004 Apr; 316(2):323-31. PubMed ID: 15020221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU.
    Pankhaniya RR; Tamura M; Allmond LR; Moriyama K; Ajayi T; Wiener-Kronish JP; Sawa T
    Crit Care Med; 2004 Nov; 32(11):2293-9. PubMed ID: 15640644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU.
    Sato H; Frank DW; Hillard CJ; Feix JB; Pankhaniya RR; Moriyama K; Finck-Barbançon V; Buchaklian A; Lei M; Long RM; Wiener-Kronish J; Sawa T
    EMBO J; 2003 Jun; 22(12):2959-69. PubMed ID: 12805211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU.
    Sato H; Feix JB; Frank DW
    Biochemistry; 2006 Aug; 45(34):10368-75. PubMed ID: 16922513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa Type III Secretory Toxin ExoU and Its Predicted Homologs.
    Sawa T; Hamaoka S; Kinoshita M; Kainuma A; Naito Y; Akiyama K; Kato H
    Toxins (Basel); 2016 Oct; 8(11):. PubMed ID: 27792159
    [No Abstract]   [Full Text] [Related]  

  • 6. ExoU is a potent intracellular phospholipase.
    Sato H; Frank DW
    Mol Microbiol; 2004 Sep; 53(5):1279-90. PubMed ID: 15387809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review.
    Sawa T; Shimizu M; Moriyama K; Wiener-Kronish JP
    Crit Care; 2014 Dec; 18(6):668. PubMed ID: 25672496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU.
    Lee VT; Pukatzki S; Sato H; Kikawada E; Kazimirova AA; Huang J; Li X; Arm JP; Frank DW; Lory S
    Infect Immun; 2007 Mar; 75(3):1089-98. PubMed ID: 17178785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors.
    Phillips RM; Six DA; Dennis EA; Ghosh P
    J Biol Chem; 2003 Oct; 278(42):41326-32. PubMed ID: 12915403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional regions of the Pseudomonas aeruginosa cytotoxin ExoU.
    Rabin SD; Hauser AR
    Infect Immun; 2005 Jan; 73(1):573-82. PubMed ID: 15618197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU.
    Saliba AM; Nascimento DO; Silva MC; Assis MC; Gayer CR; Raymond B; Coelho MG; Marques EA; Touqui L; Albano RM; Lopes UG; Paiva DD; Bozza PT; Plotkowski MC
    Cell Microbiol; 2005 Dec; 7(12):1811-22. PubMed ID: 16309466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of cytotoxicity mediated by the type III secretion toxin ExoU from Pseudomonas aeruginosa.
    Gendrin C; Contreras-Martel C; Bouillot S; Elsen S; Lemaire D; Skoufias DA; Huber P; Attree I; Dessen A
    PLoS Pathog; 2012; 8(4):e1002637. PubMed ID: 22496657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of phospholipase activity of the Pseudomonas aeruginosa type III cytotoxin, ExoU.
    Sato H; Feix JB; Hillard CJ; Frank DW
    J Bacteriol; 2005 Feb; 187(3):1192-5. PubMed ID: 15659695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eukaryotic localization, activation and ubiquitinylation of a bacterial type III secreted toxin.
    Stirling FR; Cuzick A; Kelly SM; Oxley D; Evans TJ
    Cell Microbiol; 2006 Aug; 8(8):1294-309. PubMed ID: 16882033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel phosphatidylinositol 4,5-bisphosphate binding domain mediates plasma membrane localization of ExoU and other patatin-like phospholipases.
    Tyson GH; Halavaty AS; Kim H; Geissler B; Agard M; Satchell KJ; Cho W; Anderson WF; Hauser AR
    J Biol Chem; 2015 Jan; 290(5):2919-37. PubMed ID: 25505182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Rickettsia prowazekii ExoU homologue possesses phospholipase A1 (PLA1), PLA2, and lyso-PLA2 activities and can function in the absence of any eukaryotic cofactors in vitro.
    Housley NA; Winkler HH; Audia JP
    J Bacteriol; 2011 Sep; 193(18):4634-42. PubMed ID: 21764940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of the effector ExoU from
    Springer TI; Reid TE; Gies SL; Feix JB
    J Biol Chem; 2019 Dec; 294(50):19012-19021. PubMed ID: 31662432
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity.
    Veesenmeyer JL; Howell H; Halavaty AS; Ahrens S; Anderson WF; Hauser AR
    Infect Immun; 2010 Aug; 78(8):3346-57. PubMed ID: 20479080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of ExoU phospholipase activity requires specific C-terminal regions.
    Schmalzer KM; Benson MA; Frank DW
    J Bacteriol; 2010 Apr; 192(7):1801-12. PubMed ID: 20097856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylinositol 4,5-Bisphosphate-Dependent Oligomerization of the Pseudomonas aeruginosa Cytotoxin ExoU.
    Zhang A; Veesenmeyer JL; Hauser AR
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.